News|Articles|January 20, 2020

QxP Recognizes MHRA for its Support in Development of First VR Platform for Sterile Manufacturing

The UK’s MHRA has been recognized for its support of the development of an on-demand educational platform leveraging the power of virtual reality (VR), Virtuosi, from Quality Executive Partners (QxP).

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has been recognized for its support of the development of an on-demand educational platform leveraging the power of virtual reality (VR), Virtuosi, from Quality Executive Partners (QxP).

In a Jan. 7, 2020 press release, QxP revealed that a team of five senior sterile experts from MHRA’s GMP Inspectorate participated in the pilot program as a primary beta partner. These experts reviewed select educational lecture content and VR experiences that have been created to simulate daily operations within controlled manufacturing and microbiology laboratory settings.

“We are so pleased to have the benefit of MHRA’s review and perspectives within our Virtuosi Sterile Manufacturing and Microbiology series,” said Crystal Mersh, CEO of QxP, in the press release. “The MHRA team has been a key regulatory supporter during our journey in developing this commercial VR educational technology. In fact, MHRA received our first deployed VR workstation, which in January 2020 is being upgraded to the full commercial release, providing an innovative source of internal training for the MHRA GMP Inspectorate.”

Source: Virtuosi

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.